FLAVOUR Study: FLow profiles And postoperative VasOplegia after continUous-flow left ventriculaR assist device implantation.
Axial flow
Cardiac vasoplegia syndrome
Centrifugal flow
Centrifugal flow with artificial pulse
Continuous-flow left ventricular assist device
Flow profile
Morbidity
Mortality
Outcomes
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
received:
01
05
2023
accepted:
12
12
2023
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
aheadofprint
Résumé
This study aims to associate the incidence of postoperative vasoplegia and short-term survival to the implantation of various left ventricular assist devices differing in hemocompatibility and flow profiles. The overall incidence of vasoplegia was 25.3% (73/289 patients) and 30.3% (37/122), 25.0% (18/72), and 18.9% (18/95) in the axial flow (AXF), centrifugal flow (CF), and centrifugal flow with artificial pulse (CFAP) group, respectively. Vasoplegia was associated with longer intensive care (ICU) and hospital length of stay (LOS) and mortality. ICU and in-hospital LOS and 1-year mortality were the lowest in the CFAP group. Post hoc analysis resulted in a p-value of 0.43 between AXF and CF; 0.35 between CF and CFAP; and 0.06 between AXF and CFAP. Although there is a trend in diminished incidence of vasoplegia, pooled logistic regression using flow profile and variables that remained after feature selection showed that flow profile was not an independent predictor for postoperative vasoplegia.
Identifiants
pubmed: 38300356
doi: 10.1007/s12265-023-10476-5
pii: 10.1007/s12265-023-10476-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241–51.
doi: 10.1056/NEJMoa0909938
pubmed: 19920051
Florisson DS, Conte SM, De Bono JA, Newcomb AE. Interact Cardiovasc Thorac Surg. 2019;29:844–51.
doi: 10.1093/icvts/ivz202
pubmed: 31436825
Zimpfer D, Gustafsson F, Potapov E, et al. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE registry. Eur Heart J. 2020;41:3801–9.
doi: 10.1093/eurheartj/ehaa639
pubmed: 33107561
Numan L, Ramjankhan FZ, Oberski DL, et al. Propensity score-based analysis of long-term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support. ESC Heart Fail. 2021;8:1596–603.
doi: 10.1002/ehf2.13267
pubmed: 33635573
pmcid: 8006731
Felix SEA, Oerlemans MIF, Ramjankhan FZ, et al. One year improvement of exercise capacity in patients with mechanical circulatory support as bridge to transplantation ESC. Heart Fail. 2021;8:1796–805.
Mehra MR, Cleveland JC Jr, Uriel N, et al. Primary results of long-term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implants. Eur J Heart Fail. 2021;23:1392–400.
doi: 10.1002/ejhf.2211
pubmed: 33932272
Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-year outcomes in patients with fully magnetically levitated vs axial-flow left ventricular assist devices in the MOMENTUM 3 randomized trial. JAMA. 2022;328:1233–42.
doi: 10.1001/jama.2022.16197
pubmed: 36074476
pmcid: 9459909
Moazami N, Fukamachi K, Kovayashhi M, et al. Axial and centrifugal continuous-flow rotary pumps: a translation from pump mechanics to clinical practice. J Heart Lung Transplant. 2013;32:1–11.
doi: 10.1016/j.healun.2012.10.001
pubmed: 23260699
Mehra MR. The burden of haemocompatibility with left ventricular assist systems: a complex weave. Eur Heart J. 2019;40:673–7.
doi: 10.1093/eurheartj/ehx036
pubmed: 28329374
Rangasamy S, Madan S, Saeed O, Goldstein DJ, Jorde UP, Negassa A, Patel SR. Noninvasive measures of pulsatility and blood pressure during continuous-flow left ventricular assist device support. ASAIO J. 2019;65:241–6.
doi: 10.1097/MAT.0000000000000805
pubmed: 29734257
Cowger JA, Estep JD, Rinde-Hoffman DA, et al. Variability in blood pressure assessment in patients supported with the HeartMate 3. ASAIO J. 2022;68:374–83.
doi: 10.1097/MAT.0000000000001497
pubmed: 34172641
Garcia-Ponce A, Citalán-Madrid AF, Velázquez-Avila M, Vargas-Robles H, Schnoor M. The role of actin-binding proteins in the control of endothelial barrier integrity. Thromb Haemost. 2015;113:20–36.
doi: 10.1160/TH14-04-0298
pubmed: 25183310
Komarova YA, Kruse K, Mehta D, Malik AB. Protein interactions at endothelial junctions and signalling mechanisms regulating endothelial permeability. Circ Res. 2017;120:179–206.
doi: 10.1161/CIRCRESAHA.116.306534
pubmed: 28057793
pmcid: 5225667
Deng MC, Edwards LB, Hertz MI. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report—2005. J Heart Lung Transplant. 2005;24:1182–7.
doi: 10.1016/j.healun.2005.07.002
pubmed: 16143231
Tecson KM, Lima B, Lee AY, et al. Determinants and outcomes of vasoplegia following left ventricular assist device implantation. J Am Heart Assoc. 2018;7:e008377.
doi: 10.1161/JAHA.117.008377
pubmed: 29773577
pmcid: 6015358
De Waal EEC, van Zaane B, van der Schoot MM, Huisman A, Ramjankhan F, van Klei WA, Marczin N. Vasoplegia after implantation of a continuous flow left ventricular assist device: incidence. outcomes and predictors. BMC Anesthesiol. 2018;18:185.
doi: 10.1186/s12871-018-0645-y
pubmed: 30526494
pmcid: 6286572
Swan JT, Iso T, Rizk E, et al. Defining vasoplegia following durable. Continuous flow left ventricular assist device implantation. ASAIO J. 2022;68:46–55.
doi: 10.1097/MAT.0000000000001419
pubmed: 34227791
Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP, Tidmarsh GF. Angiotensin II for the treatment if high-output shock-3 (ATHOS-3): protocol for a phase III. double-blind. randomized controlled trial. Crit Care Resusc. 2017;19:43–9.
pubmed: 28215131
Kormos RL, Antonides CFJ, Goldstein DJ, et al. Updated definitions of adverse events for trials and registries of mechanical circulatory support: a consensus statement of the mechanical circulatory support academic research consortium. J Heart Lung Transplant. 2020;39:735–50.
doi: 10.1016/j.healun.2020.03.010
pubmed: 32386998
Van Buuren S, Groothuis-Oudshoorn K. mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1–67.
doi: 10.18637/jss.v045.i03
Levy B, Fritz C, Tahon E, Jacquot A, Auchet T, Kimmoun A. Vasoplegia treatments: the past, the present, and the future. Crit Care. 2018;22:52.
doi: 10.1186/s13054-018-1967-3
pubmed: 29486781
pmcid: 6389278
Forstermann U, Sessa W. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-37–37a-d.
doi: 10.1093/eurheartj/ehr304
pubmed: 21890489
Bansal A, Uriel N, Colombo PC, et al. Effects of a fully magnetically levitated centrifugal-flow or axial-flow left ventricular assist device on von Willebrand factor: a prospective multicenter clinical trial. J Heart Lung Transplant. 2019;38:806–16.
doi: 10.1016/j.healun.2019.05.006
pubmed: 31147187
Mehra MR, Naka Y, Uriel N, et al. A fully magnetically levitated circulatory pump for advanced heart failure. N Engl J Med. 2017;376:440–50.
doi: 10.1056/NEJMoa1610426
pubmed: 27959709
Raja SG, Fida N. Should angiotensin converting enzyme inhibitors/angiotensin II receptor antagonists be omitted before cardiac surgery to avoid postoperative vasodilation? Interact Cardiovasc Thorac Surg. 2008;7:470–5.
doi: 10.1510/icvts.2007.174698
pubmed: 18272542
Caruso R, Caselli C, Cozzi L, et al. Myocardial interleukin-6 in the setting of left ventricular mechanical assistance: relation with outcome and C-reactive protein. Clin Chem Lab Med. 2015;53:1359–66.
doi: 10.1515/cclm-2014-0633
pubmed: 25411996
Sut C, Tariket S, Chou ML, et al. Duration of red blood cell storage and inflammatory marker generation. Blood Transfus. 2017;15:145–52.
pubmed: 28263172
pmcid: 5336336
Alfirevic A, Xu M, Johnston D, Figueroa P, Koch CG. Transfusion increases the risk for vasoplegia after cardiac operations. Ann Thorac Surg. 2011;92:812–9.
doi: 10.1016/j.athoracsur.2011.04.020
pubmed: 21788009
Fukamachi K, Karimov JH, Sunagawa G, et al. Generating pulsatility by pump speed modulation with continuous-flow total artificial heart in awake calves. J Artif Organs. 2017;20:381–5.
doi: 10.1007/s10047-017-0958-5
pubmed: 28391521
pmcid: 5632582
Naito N, Nishimura T, Iizuka K, et al. Rotational speed modulation used with continuous-flow left ventricular assist device provides good pulsatility. Interact Cardiovasc Thorac Surg. 2018;26:119–23.
doi: 10.1093/icvts/ivx236
pubmed: 29049782
Martinolli M, Biasetti J, Zonca S, Polverelli L, Vergara C. Extended finite element method for fluid-structure interaction in wave membrane blood pump. Int J Numer Meth Biomed Engngn. 2021;37:e3467.
doi: 10.1002/cnm.3467
Henn MC, Mokadam NA. Total artificial heart as a bridge to transplantation. Curr Opin Organ Transplant. 2022;27:222–8.
doi: 10.1097/MOT.0000000000000982
pubmed: 35649113
Nubret K, Barandon L, Haddadi M, Garrigue S. In-vivo assessment of a novel wireless systole-synchronized left ventricular assist device for temporary or permanent use. Abstract nr 000306, EACTS 2021 Barcelona.
Allen SR, Slaughter MS, Ahmed MM, et al. Competence trial: the EvaHeart 2 continuous flow left ventricular assist device. J Heart Lung Transplant. 2023;42:33–9.
doi: 10.1016/j.healun.2022.10.011
pubmed: 36347767